Gsk (GSK) Income from Non-Controlling Interests (2009 - 2026)

Gsk's Income from Non-Controlling Interests history runs 18 years deep, the most recent figure standing at $741.9 million for Q2 2026.

• In Q2 2026, Income from Non-Controlling Interests fell 66.21% year-over-year to $741.9 million; the TTM figure through Jun 2026 stood at $14.5 billion (up 74.46% YoY), while the FY2025 annual figure was $755.5 million, up 57.19% from the prior year.
• Income from Non-Controlling Interests for Q2 2026 stood at $741.9 million, down from $2.5 billion in the prior quarter.
• The five-year high for Income from Non-Controlling Interests was $18.3 billion in Q4 2022, with the low at $84.5 million in Q3 2024.
• The 5-year median for Income from Non-Controlling Interests is $2.2 billion (2025), against an average of $4.1 billion.
• The sharpest annual moves came in 2024 and 2025: Income from Non-Controlling Interests sank 95.65% in 2024, then surged 3325.55% in 2025.
• Gsk's Income from Non-Controlling Interests stood at $18.3 billion in 2022, then plunged by 64.04% to $6.6 billion in 2023, then slumped by 42.51% to $3.8 billion in 2024, then soared by 120.86% to $8.4 billion in 2025, then slumped by 91.13% to $741.9 million in 2026.
• Business Quant data shows GSK's Income from Non-Controlling Interests at $741.9 million in Q2 2026, $2.5 billion in Q1 2026, and $8.4 billion in Q4 2025.